Ranexa
Navigation Links
Ranexa in Medical News
...injection for use as a pharmacologic stress agent in radionuclide
myocardial perfusion imaging in patients unable to undergo adequate
exercise stress. ranexa is also approved for use in the European Union as
add-on therapy for the symptomatic treatment of patients with stable angina
pectoris who are inadequ...
... launching Camptosar at Pharmacia. Fong holds a B.S. from University of California, Los Angeles in Psychology. "Jim did a great job at the launch of ranexa and streamlining CVT's commercial operations. With his prior expertise in marketing and sales, and the launch of a novel blockbuster anti-cancer agent...
...I-36 study could support expansion of the existing ranexa indication to first line angina. In September 2007...d a significant reduction in cautionary language. ranexa is currently indicated for the treatment of chroni...al designed to evaluate the efficacy and safety of ranexa during acute and long-term treatment in 6,560 pati...
CVT Announces That FDA Continues to Review Ranexa(R) Applications
... data from the MERLIN TIMI-36 study could support expansion of the existing ranexa indication to first line angina. Following submission of the initial sNDA...otential HbA1c reduction claims in patients with coronary artery disease. ranexa is currently indicated for the treatment of chronic angina in patients who ...... launching Camptosar at Pharmacia. Fong holds a B.S. from University of California, Los Angeles in Psychology. "Jim did a great job at the launch of ranexa and streamlining CVT's commercial operations. With his prior expertise in marketing and sales, and the launch of a novel blockbuster anti-cancer agent...
FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R)
...ing expansion to the approved product labeling for ranexa to include a first line angina indication and a si... in the MERLIN TIMI-36 study. Patients receiving ranexa had a 37 percent reduction in their relative risk ...I-36 study could support expansion of the existing ranexa indication to first line angina. ...Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
...ns subject to closing conditions including obtaining certain third party consents, is expected in mid-November. "Jim did a great job at the launch of ranexa and streamlining CVT's commercial operations. With his prior expertise in marketing and sales, and the launch of a novel blockbuster anti-cancer agent...CV Therapeutics Reports 2007 Third Quarter Financial Results
...revenue. The $18.4 million of net product sales of ranexa in the quarter ended September 30, 2007 represents...consisted of $45.7 million of net product sales of ranexa and $14.7 million of collaborative research revenu...d to the completion of the MERLIN TIMI-36 study of ranexa and lower regadenoson research and development exp...Ranexa(R) Significantly Reduces Ischemia in Women in MERLIN TIMI-36 Study
...ation of the safety and efficacy we have seen with ranexa in other clinical trials and in commercial use," s...I-36 study could support expansion of the existing ranexa indication to first line angina. In September 2007...d a significant reduction in cautionary language. ranexa is currently indicated for the treatment of chroni......I-36 study could support expansion of the existing ranexa indication to first line angina. In September 2007...d a significant reduction in cautionary language. ranexa is currently indicated for the treatment of chroni...al designed to evaluate the efficacy and safety of ranexa during acute and long-term treatment in 6,560 pati...
Ranexa in Medical Technology
CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
-- New Preclinical Information May Correlate with Clinical HbA1c Reductions Observed in Phase 3 CARISA and MERLIN TIMI-36 Clinical Trials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that researchers have completed preliminary preclinical studi......565) in the MERLIN- TIMI 36 study. Additionally, ranexa significantly improved all measures of exercise pe...al designed to evaluate the efficacy and safety of ranexa during acute and long-term treatment in 6,560 pati...ally, according to the American Heart Association. ranexa has anti- ischemic effects which do not depend on ...
New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
...ons in hemoglobin A1c (HbA1c) levels observed with ranexa in cardiovascular patients with diabetes from the ...yndromes and diabetes) clinical trials. In CARISA, ranexa reduced HbA1c levels by an average of up to 0.7 percentage points. In MERLIN-TIMI 36, ranexa lowered HbA1c versus placebo by an average of 0.43......udy Group. In patients with diabetes treated with ranexa in the study, at four months HbA1c had declined ap...nts compared to placebo (p<0.001). Patients taking ranexa were significantly more likely (p<0.001) to achiev...0 percent, with 59 percent of diabetic patients on ranexa achieving this target at four months. Patients wi...
CV Therapeutics Announces Topline MERLIN TIMI-36 Results
...al designed to evaluate the efficacy and safety of ranexa during acute and long-term treatment in approximat...in the study and randomized to receive intravenous ranexa or placebo, followed by long-term outpatient treatment with ranexa extended-release tablets or placebo. All patients ......no evidence of increased mortality attributable to ranexa based on two year survival rates of ROLE participa...rcent of eligible CARISA patients chose to receive ranexa in the ROLE program. The mean duration of fol...l dosing, 9.7 percent of patients had discontinued ranexa due to adverse events. No treatment discontinuat...
Ranexa in Biological Technology
CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal
...ish a solid cash position. The full promotional launch of the improved U.S. ranexa labeling is just beginning, the introduction of ranexa in Europe is imminent, and Lexiscan is showing real growth in the marketpla...CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
... $100 million in convertible debt in 2008 - - ranexa prescriptions for first week in February hit recor...an $250 million in non-dilutive net cash, grew our ranexa business by 64 percent year-over-year, and saw our..., the full promotional launch of the improved U.S. ranexa labeling and the imminent introduction of...CV Therapeutics Reports 2008 Third Quarter Financial Results
... Astellas and $0.3 million of amortization of our $70.0 million upfront license payment from the Menarini Group (Menarini) for the exclusive rights to ranexa in the European Union and certain other countries. The $3.2 million of collaboration, milestone and other revenue includes a $3.0 million milestone pa......- New labeling reinforces strong safety profile of ranexa - - Conference call scheduled for 8:00 a.m. ET/5...disease. In addition, the new labeling states that ranexa reduces hemoglobin A1c (HbA1c) in patients with diabetes. According to the revised labeling, ranexa is indicated for the treatment of chronic angina a...
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
...total, the agreement grants rights to Menarini for ranexa in 68 countries, including the 27 countries of the...e development milestones are linked to approval of ranexa in Europe for certain additional indications that ... of physician details and promotional spending for ranexa for a specified period of time. In addition to u......injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. ranexa is also approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequ...
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
...injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. ranexa is also approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequ...CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
...he brand name Latixa. "Securing approval for the ranexa brand name in Europe provides important brand syne... and chief executive officer of CV Therapeutics. ranexa is approved for use in Europe as an add-on therapy...tients unable to undergo adequate exercise stress. ranexa is also approved for use in the European Union as ...CV Therapeutics Reports 2008 Second Quarter Financial Results
... - ranexa Revenue Grows 15 Percent Quarter-over-Quarter - PALO ALTO, Calif., July 3...pared to the prior quarter ended March 31, 2008 was primarily due to higher ranexa marketing and sales expense. The decrease in costs and expenses in the qu...CV Therapeutics Reports 2008 First Quarter Financial Results
...revenue. The $22.0 million of net product sales of ranexa in the quarter ended March 31, 2008 represents an ...ssociated with various development projects, lower ranexa marketing and sales expenses and lower general and...d to the completion of the MERLIN TIMI-36 study of ranexa and lower regadenoson research and development exp...Other TagsDomeDomeDomeSPRSPRSPRSPRSPRSPRSPROther Contentssequencesequencesequencesequencesequencesequencesequencesequencesequencesequencerepeatedrepeatedrepeatedrepeatedrepeatedrepeatedrepeatedrepeatedrepeatedrepeatedreplicationreplicationreplicationreplicationreplicationreplicationreplicationreplicationreplicationenzymeenzymeenzymeenzymeenzymeenzymeenzymeenzymeenzymerespirationrespirationrespirationrespirationrespirationrespirationreversereversereversereversereversereversereversereversereverseretrovirusretrovirusretrovirusretrovirustypetypetypetypetypetypetypetypetypetype
AATAREDSformulasGelCapsDomeCONDUCTRSPRPhototherapyAFSCHypergammaDensitometerSpirometerExfoliatingResorcinol
(Date:12/15/2009)... cancer tests promised but not delivered ,, ... calls on Congress to ensure that healthcare reform ... currently required of insurance companies in 37 states. ... those segments of the population and individuals who ... men and men who have a family history ...
(Date:12/15/2009)... -- Knowledge Networks is significantly ... bio-tech research market with the acquisition of ... 11 years CMR has built and grown ... which now includes 70,000 U.S. physicians, and ... and hard-to-reach specialties. The Mount-Arlington, NJ-based ...
(Date:12/15/2009)... Team In Training (TNT), The Leukemia & Lymphoma ... program, has reached a remarkable milestone of raising ... patient services. ,, For more than 21 years, ... training program, preparing amateurs and seasoned athletes to ... cycle ride or hike adventure. Through the program,s ...
(Date:12/15/2009)... YORK, Dec. 15 The following are the ... General for the criminal division, at the Medicare ... Secretary Sebelius. And thank you for the enormous ... HEAT initiative. ,, Together, our Departments have ... results. ,, We,ve made tremendous progress in fighting ...
(Date:12/15/2009)... American application activity for individually underwritten life insurance ... MIB Life Index(SM) . Solid growth ... months have lifted year-to-date (YTD) figures from their ... November,s close, -0.1%. "It is clear consumers ... from life insurance," says Stacy Gill, MIB Solutions, ...
Breaking Medicine News(10 mins):Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3[1] Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform[1] Knowledge Networks Expands in Pharma Research With Acquisition of CMR[0] $1 Billion - For Charity![1] Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference[1] MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November
(Date:12/15/2009)... Economics, environmental impacts, social dynamics, and production levels ... success of an agroecosystem. Positive or negative, these ... and social groups to continuously adapt farming and ... Experiential learning theory suggests that knowledge is gained ... lessons are especially valuable for environmental and agricultural ...
(Date:12/15/2009)... American horses may have been grazing the North ... previously thought. After plucking ancient DNA from frozen ... used cutting-edge techniques to uncover "genetic fossils" of ... between 7,600 and 10,500 calendar years. This new ... these now-extinct mammals endured longer in the continental ...
(Date:12/15/2009)... This release is available in German ... use in predicting the future distribution of mammals. This ... niches of 140 indigenous European mammals. The researchers analysed ... as well as the phylogenetic information of the species. ... for closely related species, mammals seem to adapt fast ...
Breaking Biology News(10 mins):Experiential learning teaches change and adaptation 2Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4Species distribution models are of only limited value for predicting future mammal distributions 2Euro RSCG Life Acquires Medicom Group to Further Strengthen Its Global and European Medical Education Offering 50550 1Euro RSCG Life Acquires Medicom Group to Further Strengthen Its Global and European Medical Education Offering 50550 2Everock Inc Completes Reverse Merger with Privately Held All Natural Food Producer Natures Peak 50545 1Everock Inc Completes Reverse Merger with Privately Held All Natural Food Producer Natures Peak 50545 2Everock Inc Completes Reverse Merger with Privately Held All Natural Food Producer Natures Peak 50545 3The Other Cruciate Ligament 3A Newer Treatments for PCL Tears 50542 1The Other Cruciate Ligament 3A Newer Treatments for PCL Tears 50542 2The Other Cruciate Ligament 3A Newer Treatments for PCL Tears 50542 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |